Contractile responses evoked by dihydroergotamine, naratriptan and sumatriptan in the canine isolated coronary artery

Fundamental and Clinical Pharmacology

Volumn 12, Issue 2, 1998, Pages 152-157

  Valentin, J P ^a   Bonnafous, R ^a   John, G W ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT(1B D) receptors; Coronary artery; Dihydroergotamine; Endothelial dysfunction; Naratriptan; Sumatriptan

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; DIHYDROERGOTAMINE; N(G) NITROARGININE METHYL ESTER; NARATRIPTAN; NITRIC OXIDE SYNTHASE; SEROTONIN AGONIST; SUMATRIPTAN;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY; DOG; ENDOTHELIUM; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; VASOCONSTRICTION;

EID: 0031967879     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00935.x     Document Type: Article

References (35)

1. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijssen EJM, Bos E, Saxena PR. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993 ; 239 : 203-10
2. Brazenor RM, Angus JA. Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol 1982 ; 81 : 569-76
3. 2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation 1993 ; 87 : 874-80
4. 2-receptor agonist, U46619. Br J Pharmacol 1993 ; 110 : 360-8
5. 2-serotoninergic blockade. J Pharmacol Exp Ther 1986; 237 : 548-52
6. 2 receptor activation. Eur J Pharmacol 1989 ; 161 : 91-4
7. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PPA. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997 ; 17 : 145-52
8. Cushing DJ, Cohen ML. Comparison of the serotonin receptors that mediate smooth muscle contraction in canine and porcine coronary artery. J Pharmacol Exp Ther 1992 ; 261 : 856-62
9. 1D-like receptor. Life Sciences 1994 ; 54 : 1671-80
10. Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995 ; 40: 245-51
11. Frenken M, Kaumann AJ. Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog. Naunyn-Schmiedeberg's Arch Pharmacol 1985 ; 328 : 301-3
12. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988 ; 94 : 1123-32
13. 1Dβ receptors. Circulation 1994 ; 90 : 1141-53
14. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990 ; 66 : 1561-75
15. Kemp BK, Cocks TM. Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro. Br J Pharmacol 1995 ; 116 : 2183-90
16. 1-receptor agonist for the treatment of migraine. Br J Clin Pharmacol 1993 ; 36 : 170P (abstr)
17. Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA. 5-HT receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol 1996 ; 42 : 431-41
18. Luscher TF, Richard V, Tschudi M, Yang Z, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries, J Am Coll Cardiol 1990 ; 15 : 519-27
19. Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. In: Luscher TF, Vanhoutte PM. Boca Raton: CRC Press; 1990. p 1-228
20. Maassen VanDenBrink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1996 ; 119 : 855-62
21. 1 receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone. Pulm Pharmacol 1994 ; 7 : 65-72
22. Marquardt DW. An algorithm for least squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963 ; 11 : 431
23. McCulloch KM, Templeton AG, MacLean MR. Effect of nitric oxide synthase inhibitor on contractile responses to sumatriptan in bovine pulmonary arteries. Thorax 1994 ; 49 : 426 (abstr)
24. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. New EnglJ Med 1993 ; 329 : 2002-12
25. 1-like receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1992 ; 346 : 592-6
26. Sakanashi M, Yonemure KI. On the mode of action of ergometrine in the isolated dog coronary artery. Eur J Pharmacol 1980 ; 64 : 157-60
27. Saxena PR, De Vries P, Heiligers JPC, Maassen VanDenBrink A, Bax WA et al. Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol 1996 ; 312 : 53-62
28. 1Dα receptor subtype expression in canine large coronary arteries and saphenous vein. Cardiovasc Res 1996 ; 31 : 793-9
29. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997 ; 37 suppl 1 : S15-S25
30. Sweeney G, Templeton A, Clayton RA, Baird M, Sheridan S, Johnston ED, MacLean MR. Contractile responses to sumatriptan in isolated bovine pulmonary artery rings: relationship to tone and cyclic nucleotide levels. J Cardiovasc Pharmacol 1995 ; 26 : 751-60
31. 1-like receptor mediating contraction in the canine coronary artery. Eur J Pharmacol 1996 ; 300 : 109-12
32. 1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 1996 ; 119 : 35-42
33. Vanhoutte PM, Shimokawa H. Endothelium derived relaxing factor(s) and coronary vasospasm. Circulation 1989 ; 80 : 1-9
34. 1D receptor agonists, sumatriptan and naratriptan in anesthetized, open-chest pigs. Cephalalgia 1995 ; 15 suppl 14 : P9 (abstr)
35. 1-like receptors by endogenous nitric oxide. Br J Pharmacol 1995 ; 114 : 969-74